Diabetic Retinopathy Market

Diabetic retinopathy is among the leading causes of legal blindness among the working-age adults worldwide. Anticipated increase in prevalence of diabetes prevalence indicates that diabetic retinopathy will continue to the prevalence of vision loss in the future. Diabetes and diabetes related complications carry heavy economic burden. Estimates also suggest that diabetic retinopathy alone contributes 10% to 42% of direct medical costs, whereas the indirect costs could be much higher. Surgical treatments have been preferred for a long time for diabetic retinopathy treatment at severe stages. Several pharmacological treatments are introduced and many are in development for treating this complication. This report studies the global and regional markets for various diabetic retinopathy treatments currently available.

For the purpose of this study, the global diabetic retinopathy market is assessed for diabetic retinopathy treatment devices and drugs. The devices market is categorized into focal laser treatment, scatter laser treatment and vitrectomy devices. the diabetic retinopathy treatment drugs is studied for aflibercept (Eylea), bevacizumab (Avastin), fluocinolone acetonide (Iluvien), ranibizumab (Lucentis) and triamcinolone acetonide. Global market size and forecast for the mentioned segments for the period 2014-2022 along with corresponding CAGRs for the forecast period 2016-2022 are included in this section.

Geographically, the global diabetic retinopathy market is studied for the following regional markets:

North America

a.    U.S.

b.    Canada

Europe

a.    U.K.

b.    Germany

c.    Rest of Europe

Asia-Pacific

a.    Japan

b.    China

c.    Rest of Asia-Pacific

Middle East and Africa

Latin America

The market size and forecast for the period 2014-2022 along with the CAGRs for the period 2016-2022 for the mentioned segments are also presented in this study.

Qualitative information sets such as market dynamics (drivers, challenges, future prospects) and market inclination insights are provided in this market assessment report. Tools such as competition assessment and attractive investment proposition are also included in this study for studying the global market competition. The report concludes with company profiles section that highlights key information about the major market players operating in the global diabetic retinopathy market.

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology

Chapter 2 Executive Summary
2.1 Diabetic Retinopathy Treatment Devices Market, by Type, 2015 (USD Mn)
2.2 Diabetic Retinopathy Treatment Drugs Market, by Type, 2015 (USD Mn)
2.3 Diabetic Retinopathy Market Share, by Geography, 2015 (Value %)

Chapter 3 Diabetic Retinopathy Market: Market Dynamics and Outlook
3.1 Introduction
3.2 Diabetic Retinopathy: Facts and Figures
3.3 Drivers
3.4 Challenges
3.5 Future Prospects
3.6 Attractive Investment Proposition
3.1 Competitive Analysis: Market Positioning, by Key Market Players

Chapter 4 Global Diabetic Retinopathy Treatment Devices Market Analysis, by Device Type, 2014-2022 (USD Mn)
4.1 Preface
4.2 Focal Laser Treatment
4.3 Scatter Laser Treatment
4.4 Vitrectomy Devices

Chapter 5 Global Diabetic Retinopathy Drugs Market Analysis, by Drug Type, 2014-2022 (USD Mn)
5.1 Preface
5.2 Aflibercept (Eylea)
5.3 Bevacizumab (Avastin)
5.4 Fluocinolone Acetonide (Iluvien)
5.5 Ranibizumab (Lucentis)
5.6 Triamcinolone Acetonide Injection

Chapter 6 Global Diabetic Retinopathy Market, by Geography, 2014-2022 (USD Mn)
6.1 Preface
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 U.K.
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia-Pacific
6.4.1 Japan
6.4.2 China
6.4.3 Rest of Asia-Pacific
6.5 Middle East and Africa (MEA)
6.6 Latin America

Chapter 7 Company Profiles
7.1 Alimera Sciences, Inc
7.1.1 Business Description
7.1.2 Financial Health and Budget Allocation
7.1.3 Product Positions/Portfolio
7.1.4 News Coverage
7.2 Pfizer
7.2.1 Business Description
7.2.2 Financial Health and Budget Allocation
7.2.3 Product Positions/Portfolio
7.2.4 News Coverage
7.3 Genentech USA, Inc.
7.3.1 Business Description
7.3.2 Financial Health and Budget Allocation
7.3.3 Product Positions/Portfolio
7.3.4 News Coverage
7.4 Sandoz Inc.
7.4.1 Business Description
7.4.2 Financial Health and Budget Allocation
7.4.3 Product Positions/Portfolio
7.4.4 News Coverage
7.5 Bayer Pharma AG
7.5.1 Business Description
7.5.2 Financial Health and Budget Allocation
7.5.3 Product Positions/Portfolio
7.5.4 News Coverage
7.6 Regeneron Pharmaceuticals Inc.
7.6.1 Business Description
7.6.2 Financial Health and Budget Allocation
7.6.3 Product Positions/Portfolio
7.6.4 News Coverage
7.7 Sirnaomics
7.7.1 Business Description
7.7.2 Financial Health and Budget Allocation
7.7.3 Product Positions/Portfolio
7.7.4 News Coverage
7.8 Iridex Corporation
7.8.1 Business Description
7.8.2 Financial Health and Budget Allocation
7.8.3 Product Positions/Portfolio
7.8.4 News Coverage
7.9 Lumenis
7.9.1 Business Description
7.9.2 Financial Health and Budget Allocation
7.9.3 Product Positions/Portfolio
7.9.4 News Coverage
7.10 Valon Lasers OY
7.10.1 Business Description
7.10.2 Financial Health and Budget Allocation
7.10.3 Product Positions/Portfolio
7.10.4 News Coverage
7.11 Other Notable Players

List of Figures

FIG. 1 Diabetic Retinopathy: Market Segmentation
FIG. 2 Diabetic Retinopathy Treatment Devices, by Type, 2015 (USD Mn)
FIG. 3 Diabetic Retinopathy Treatment Drugs Market, Type, 2015 (USD Mn)
FIG. 4 Diabetic Retinopathy Market Share, by Geography, 2015 (Value %)
FIG. 5 Attractive Investment Proposition, Diabetic Retinopathy Market, 2015
FIG. 6 Competitive Analysis: Market Positioning, by Key Market Players
FIG. 7 Global Focal Laser Treatment Market, 2014 – 2022 (USD Mn)
FIG. 8 Global Scatter Laser Treatment Market, 2014 – 2022 (USD Mn)
FIG. 9 Global Vitrectomy Devices Market, 2014 – 2022 (USD Mn)
FIG. 10 Global Aflibercept (Eylea) Market, 2014 – 2022 (USD Mn)
FIG. 11 Global Bevacizumab (Avastin) Market, 2014 – 2022 (USD Mn)
FIG. 12 Global Fluocinolone Acetonide (Iluvien) Market, 2014 – 2022 (USD Mn)
FIG. 13 Global Ranibizumab (Lucentis) Market, 2014 – 2022 (USD Mn)
FIG. 14 Global Triamcinolone Acetonide Injection Market, 2014 – 2022 (USD Mn)
FIG. 15 U.S. Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 16 U.K. Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 17 Germany Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 18 Rest of Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 19 Japan Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 20 China Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 21 Rest of Asia-Pacific Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 22 Middle East and Africa Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
FIG. 23 Latin America Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)

List of Tables

TABLE 1 Global Diabetic Retinopathy Treatment Devices Market, by Device Type, 2014 – 2022 (USD Mn)
TABLE 2 Global Diabetic Retinopathy Drugs Market, by Drug Type, 2014 – 2022 (USD Mn)
TABLE 3 Global Diabetic Retinopathy Market, by Geography, 2014 – 2022 (USD Mn)
TABLE 4 North America Diabetic Retinopathy Market, by Country, 2014 – 2022 (USD Mn)
TABLE 5 Canada Diabetic Retinopathy Market, 2014 – 2022 (USD Mn)
TABLE 6 Europe Diabetic Retinopathy Market, by Country, 2014 – 2022 (USD Mn)
TABLE 7 Asia-Pacifc Diabetic Retinopathy Market, by Country, 2014 – 2022 (USD Mn)